Archive for category Biotech – Medical Device – Life Science – Healthcare

WSGR 2017 Medical Device Conference

With shrinking pool of serious early stage life science investors and stringent capital requirements, the path for medtech companies has become greatly challenging.  As is the case every year, Wilson Sonsini Goodrich & Rosati 2017 Medical Device Conference provided a forum for addressing challenges faced by new medtech companies as well as opportunities presented by current trends.

Various speakers and panels addressed these issues from diverse angles and perspectives.  Following a welcome address by
Casey McGlynn, an early morning panel moderated by Donna Petkanics addressed new models for medtech investing.  Panelists Andrew ElBardissi (Deerfield Capital), Eric Milledge (Endeavor Vision SA), Leighton Read (Brandon Capital Partners), and Valeska Schroeder (KCK Group)  discussed how the investors are adapting their financing strategies and business models in response to the newer challenges that medical device companies face.  Milledge opined that it is now crucial for medtech companies to get some regulatory approval before seeking to raise money. Even CE mark could help, said Milledge. ElBardissi offered that if the company is US based and focused on US commercialization strategy then EU approval does not help. He advised that medtech companies “keep the head down and focus on US approval UNLESS there is capital efficient advantage of focusing on EU”. Schroeder said their fund was “geographically agnostic” but they believed that for an early stage medtech company it is important that they not “simply throw capital without a plan”.  but there are values you can get out which may not be revenue based but you can get close to your customer base etc… not go in every country but choosing a small no. of country to go through. Read observed that a company seeking to create larger returns must go after larger markets.

Image result for wilson sonsini medical device conference 2017With the current challenges medtech world has become more global as companies and investors are finding win-win solutions through newer models of partnering by going across continents and countries. Geographically, Pacific Rim has emerged as hot collaboration frontier. A panel moderated by Elton Satusky with CEOs Yue-Teh Jang (Medeon Biodesign), Kewen Jin (Serica Partners, Trevor Moody (M. H. Carnegie & Company), and Norman Weldon (Partisan Management Group), who completed such collaborations, financings and mergers with companies and investors in Asia discussed how these transactions may be structured.  Another panel moderated by Jack Moorman (US-Japan MedTech Frontiers – USJMF), with panelists Kenichi Hata (Terumo Corporation), Masazumi Ishii (AZCA Inc.), Yuichiro Morimoto (Enplas Corporation), and Richard Packer (Asahi Kasei Corporation) discussed collaborations between Japan and Silicon Valley.  Japan has emerged as a major partner in medtech OUS financing and growth strategy.  

Image result for medtech investmentIncreasingly there is a pressure on medtech industry that is unlike most other industries, to show value. Many organizations have now come up with ways to define and measure value creation. Among them, AdvaMed has developed a new framework to assess the value of medical technologies and diagnostics in a broad, patient-centric approach. A panel moderated by Donald May (AdvaMed) with panelists Maneesh Arora (Exact Sciences Corp), Jeff Farkas (Medtronic), and Jo Carol Hiatt (Kaiser Permanente) addressed how companies may leverage value creation to make internal business decisions to allow for more efficient use of capital and to drive discussions with potential investors as well as to keep track of milestones during the commercialization process.

AdvaMed model focuses on following drivers of value creation, 1) clinical outcomes, effectiveness and utility measures 2) non clinical patient impact including impact on caregivers, families, ease of product use, ease of care, financial impact etc. 3) new drivers around value based purchasing, care delivery costs, reduction in readmissions etc. from provider perspectives, and 4) broader public impact on population and communities in terms of whether or not the technology reduces overall cost to the system, helps identify diseases, helps employers reduce absenteeism and so on. May said the model begins with the patient and goes on to incorporate multiple stakeholders and values for all may not always be aligned or the time frames may differ. As an industry, “we need to think of appropriate levels and types of evidence as we think of new value based models of integrated care”, said May. Speakers discussed the need to move away from one number and focus on broad picture with many factors that include clinical as well as economic value, in order to get better outcomes while reducing costs.

Image result for wilson sonsini medical device conference 2017As is the case, WSGR medtech conference provides an excellent forum for investors, startups, and professionals in the industry to come together in a spirit of learning and collaboration. And compared to previous years, it seemed to be even more well attended with hallways abuzz with discussions on partnering. As always, the conference ended with short presentations from select few startups and the announcement of the $25,000 grand prize and Medtech Innovator Award.  But the best was reserved for the last. More networking happened and deals were done as attendees mingled with good food at the reception and as the best wines were uncorked and venture capitalists served as sommeliers and poured wine for the attendees.



, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

1 Comment

Mission to do common good through better health – 2017 HTF Innovation conference – preview

Current discussions on repeal of Obamacare has brought much focus on issues of health and wellness in America and has energized the underserved communities.  The 6th Annual Health Technology Forum Innovation Conference taking place at Stanford University on May 1 and 2, 2017 will explore health and wellness through panels and speakers, with a central focus on technology and on implementation of key health policies.
Image result for health technology innovation conference

What kind of technology innovations may effectively address the unmet needs of the underserved and underrepresented markets?  Can next generation technology solutions provide better access and improve care outcomes? These and other issues will be discussed in outstanding panels. The Innovation Showcase will offer an exclusive networking opportunity to startups and investment community to develop strategic partnerships. The high visibility demo space in the expo corridor will allow startups an opportunity to highlight their offerings.

Every year, health technology forum conference offers phenomenal opportunity to bay area health strategists, providers, venture capitalists, startups, and professionals to come together with a mission to do “common good” through better health.  Please register for the conference at .


, , , , , , , ,

Leave a comment

Immunotherapy, Bioinformatics, Devices: EPPICon 2017 Preview


One of the latest most talked about buzzwords in cancer treatment is “immunotherapy” where body’s immune system is used to wage a war against the cancer cells. Cancer cells divide rapidly than ordinary cells and manage to evade the immune system. The focus of a range of immunotherapies is to put body’s immune system on high alert so it can easily locate and destroy cancer cells.

Image result for immunotherapy, bioinformaticsThis year, EPPICon (annual flagship conference at eppicglobal at will focus on Immunotherapy, Bioinformatics, and Devices. Another recent buzzword, “bioinformatics” focuses on harnessing technological advances for management and analysis of data, for cancer immunology and immunotherapy.  The hope is that more reliable and comprehensive picture can emerge of tumor genomics landscape and that can point a way towards more effective personalized medicine.

Immunotherapy often involves delivery of a cocktail of immune drugs to awaken the body’s immune system and put it in a “ready” mode to get rid of the cancer cells. Implantable devices can be used to provide regular dosages of medication for several days or everyday for a few weeks and can be used to make localized delivery.  This convergence of technologies makes it an interesting time for treatment of cancer and other diseases.  

EPPICon, EPPIC’s all day conference will be held on Saturday, March, 25th at Crowne Plaza, Burlingame, CA and has a fabulous lineup of keynotes, speakers, and panels.

Image result for Ira Mellman, genentechMorning keynote, Ira Mellman is VP of Cancer Immunology at Genentech and has an illustrious career in solving most profound health problems with strong research, grounded in science.  He spent 20 years at Yale University School of Medicine, prior to joining Genentech in 2007.  After the keynote, the conference program will continue with excellent speakers and panels with a special speed pitch session thrown in, where startups looking for funding will have an opportunity to pitch to a panel of investors and receive critical feedback, in real time. At the end of the day, 2017 “EPPIC Eleven” awards will be given out to chosen startups, from around the globe.

To register for the conference, please go to .

, , , , , , , , , , , ,

Leave a comment

Role of IP Due Diligence in Corporate Finance

A panel moderated by Jim Hesling, at Wilson Sonsini Medical Device Conference, with Eric Bell from Spring Rock Ventures, Mir Imran from Incube Ventures, and Gwen Watanabe from Teleflex, discussed the role of IP due diligence in corporate finance.  The panel offered great advice and insights for medtech startups.

From the buy side perspective, InCube Ventures invests in mid to late stage companies and focuses specifically on disruptive innovations that change patients outcomes, said Imran.  While their focus area may be in white space of IP, depending on the technology, Incube does thorough investigation of IP, said Imran.  Also early on they assess if it is incremental innovation of existing solution or a truly disruptive concept.

Also from buy perspective, Watanabe said, during the acquisition process, they like to see entire application, talk with the team and then do complete due diligence on the patent portfolio.  Watanabe said when buying “we also deconstruct claims for validity”.  She added, “we don’t stop at patents, IP also includes grants, know hows, and any other secrets”.  Teleflex also uses software tools to map out the IP area and it operates in 160 countries. They have an external counsel going through the FTO and they pay specific attention to any potential for patent infringement.  Eric Bell from Springrock Ventures, said, they use external counsel to do thorough assessment and clearly consider issued patents versus filed patents, because when issued it provides contextual validity.

Speaking from the sell side perspective, Imran offered lot of great advice to the entrepreneurs. Imran is a serial entrepreneur with several successful companies, and advised that entrepreneur hire a litigator to review their patent portfolio to point out holes and weaknesses as well as areas of strength.  A litigator can have a vastly different perspective than a prosecutor, said Imran.  Both Bell and Imran also suggested that entrepreneurs continue to focus on the IP as the technology moves forward.  Many founders focus strongly on IP earlier and specially when fundraising but then put it on the back burner.  However, as direction changes occur, they become lax on IP and it may not allow for product to be fully covered and it can impact subsequent fundraising.  Also the patent landscape is too crowded and freedom to operate is very important, said Imran.

Panelists asserted that while ongoing IP commitment is extremely important, they agreed that IP alone does not create value.  Real value is created from total context including patient outcomes, regulatory approvals, reimbursement etc.  Some young CEOs do a press release when a patent is filed or approved and Imran advised, they not do it and Watanabe chimed in that they do it when they get FDA approval.  “One thing I do is to step back and think about how I would get around my own patents and then file more patents, so I think like a competitor”, said Imran, himself a holder of hundreds of patents.  Imran said, while patent filings are very expensive and companies can’t do it frivolously, he also suggested that companies file patents in other countries with substantial markets like India and China.  Founder should formalize the process internally in the company so that employees are keeping good lab notebooks and everything is documented to be able to defend obviousness claim, said Imran.  

PS – Please check out exciting jobs offering opportunities to work with disruptive technologies in JOBS category on this blog & please send leads or resume at wd_darshana at hot mail dot com.

Leave a comment

New Corporate Deal Models for Medtech Companies

Often continuous internal innovation is expensive and unpredictable for medtech companies, and yet in order to continue to grow their business, they need to introduce important new products.  A panel at 2016 WSGR Medical Device Conference, discussed what large companies are looking for today and how evolving deal structures can benefit both the buyer and the seller.  The panelists discussed this in context of their own stories of deal models.  On the panel moderated by Steve Levin,  were Fred Aslan from Adavium Medical, Hanson Gifford from The Foundry, Bruce Roberts from RM Global Partners, and Thierry Thaure from Cephea Valve Technology.  

Thaure discussed Abbott’s interest in Cephea and how the milestone based deal was struck.  Mitral valve disease is highly complex and requires multiple treatment options.  Abbott’s interest in Cephea emerged from the objective to complement its own portfolio of mitral valve replacement therapies.  Cephea’s catheter based mitral valve replacement therapy seemed to fit in nicely with Abbott’s Mitraclip device, for addressing this huge market opportunity.  Initially, Abbott made an equity investment, holding the option to acquire.

The Foundry built by a group of serial entrepreneurs, do a lot of inventing but additionally also look at other outside opportunities that address dramatic clinical improvement over existing treatment models.  Thus operating as a medical device incubator, The Foundry helps the companies it takes under its wings, with fundraising, recruitment and helps them to rapidly transform their concepts into companies.  Since its inception in 1998, The Foundry has founded and financed nearly a dozen medical device companies which have generated over $2 billion of value.  Ardian came out of the Foundry and was acquired in cash plus commercial milestones based deal by Medtronic.  Foundry’s some of the other successes include Cabochon Aesthetics (acquired by Ulthera), Concentric Medical (acquired by Stryker), Emphasys Medical (sold to Pulmonx), and evalve (acquired by Abbott).

Fred Aslan said while countries like Brazil, China, and India offer huge growth opportunities, navigating those markets to develop sales and marketing is very challenging as these are highly fragmented markets with mom and pop establishments and while companies should work with local distributors, it is also hard to find distributors.  With two recent acquisitions, Advium transformed itself into the largest Brazilian medical equipment and diagnostics company as measured by sales and number of customers across both specialties.  Brazil is one of the most complex and one of the largest healthcare markets in the world, after US and China.  Aligning with the needs of the market, Advium focuses heavily on aesthetics, dermatology, plastics surgery, vascular surgery, and gynecology and on clinical diagnostics.

As a senior partner, Roberts oversees the medtech M&A practice at RM Global Partners LLC, boutique investment banking and strategic advisory firm.    “Every technology we help develop is some form of global technology arbitrage”, said Roberts.  RMG helps increase the value of their clients’ innovation pipeline while helping them account for risk and uncertainty.  Besides financial and strategic advice to its clients, RMG leverages its global network to source and execute transactions to build new opportunities for their clients, worldwide.

PS – Please check out exciting jobs offering opportunities to work with disruptive technologies in JOBS category on this blog or at link & please send leads or resume at wd_darshana at hot mail dot com.

1 Comment

Medtech Emerging Models of Innovation – WSGR 2016 Medtech Conference

A breakout panel at recent Wilson Sonsini Medical Device Conference, with Scott Murano from Wilson Sonsini, Fred Toney from Lean Launchpad, Kevin Wasserstein from Neurotechnology Innovations Translator, and Ryan McGuinness from Triple Ring Tech, discussed new emerging models of innovation for medical technologies.  The panelists shared the methods they use to identify important new innovations, and how they assist in rapidly building product prototypes and help complete first-in-man cases in a cost effective manner.  

Toney, at Lean Launchpad (that was started by Steve Blank), said they cast a wide net and take several contenders through a stringent vetting process and make a final selection to invest in 6-10 companies, with fundable milestones, and clear clinical evidence.  These companies are fostered from early stage and provided guidance, teaching, and tools to understand customers in a deep way.  

At Triple Ring, the driver is to create opportunities for serendipitous events and help create a robust ecosystem and build upon the opportunities that come through the network, said McGuinness.  This model thrives best in Silicon Valley, with an existing thriving ecosystem, though they are trying to export the model to other parts of the country.  The companies are vetted through the expertise of Triple Ring staff in their specific domains.  Triple Ring invests in a small subset of companies that are incubated there but it is not a requirement of participating in the incubator.  More importantly, TRT supports interesting projects or companies with its world class R&D capability.  The focus at TRT is to move quickly to add value and reach the inflection points/ funding milestones.  When data indicates non viability of the idea, “we move quickly and kill easily and cheaply, adding value to the fail fast side of the coin”, said McGuinness.  

Neurotechnology Innovations Translator, that has come out of Ohio State, is not a VC firm but assists medtech companies by providing comprehensive clinic development resources, management and leadership expertise and helping raise investment capital.  In vetting process, Wasserstein said they look for the size of the clinical need the technology seeks to address and the market opportunity it represents.  Starting with some objective criteria, they overlay that with how the company can truly make an impact and how well it would thrive with the ecosystem they can  provide, said Wasserstein.  The Translator has access to excellent advisors, animal lab and engineers on bench for rapid testing, and onsite rapid prototyping facility to move projects forward quickly.

The panel agreed that medtech investing is not dead but companies need to stay focused on solving a problem and have the tenacity, persistence and creativity and look for out of the box resources to help them move forward.

 PS – Please check out exciting jobs offering opportunities to work with disruptive technologies in JOBS category on this blog & please send leads or resume at wd_darshana at hot mail dot com.


Leave a comment

2016 Wilson Sonsini Medical Device Conference Synopsis


2016 Wilson Sonsini Medical Device Conference took place in San Francisco.  While the tone of the conference was upbeat, there was also an acknowledgement of the challenges that medtech companies continue to face.  New and innovative models are emerging to help navigate medtech companies through the challenging landscape.

Considerable discussion focused around monetary challenges.  The conference started with a spotlight on venture capital with two new funds investing in early stage medical technology companies.  Given the shrinking pool of investors interested in medtech companies, it was uplifting to hear from Sante Ventures and Apple Tree Partners about their focus on early stage medtech companies.

Breakout sessions focused on a range of topics that would help them steer a startup through building it and taking it from concept to commercialization, in a cost effective manner.  A panel discussed emerging new methods of innovation to help the company through early prototypes and early first-in-man cases speedily.  Obtaining reimbursement in the changing healthcare system is one of the most significant challenges and a panel addressed the issue of the reimbursement puzzle and ways to accelerate the adoption of new but unreimbursed medical devices.  One panel focused on ways of creating win-win transactions with corporate investors, whereas another focused on new corporate deal models.   

New methods of innovation increasingly include partnerships and collaborations with players outside the US.  With growing interest from Japan in investing in US medtech companies, Japan has emerged as an important partners.  A panel of experts discussed ways in which Japan and Silicon Valley startups are collaborating to finance and develop advanced medical technologies.  Panels also discussed topics like Asian funding strategies and Israeli medtech revolution.  

There were also discussions around more specific technologies and topics.  Topics like off-label promotion and hiring and compensating CEOs were also discussed.  A panel of CEOs with success in launching new products and building sales organizations, discussed evolving commercialization strategies required for product adoption.  One panel focused specifically on the future of innovation in the area of percutaneous valve products that has recently revolutionized the heart valve market.  Another panel discussed IPOs and corporate buyouts and in yet another panel the focus was on role of IP due diligence in corporate finance.

Before the corks came off the wine bottles, with venture capitalists serving as sommeliers, the semi finalists chosen for MedTech Innovator award were spotlighted.  From 430 companies that presented their pitch to a panel of judges (a 30% increase from 2015), 20 semi finalists were selected to present a one minute pitch in a video.  The audience heard their pitch in a 20 minute video.  From these, four were selected to present longer pitchs and answer questions posed by a panel of judges.  The audience then voted to select one of these four and the winner received a $25,000 award.   By then it was time to uncork the wine and get better acquainted with those who poured the wine and who might pour much needed cash into medtech startups.

I will post a few different blogs on some of the panels, over the next few days.  So stay tuned.  Below are some highlights from venture capital spotlight discussion that started the morning.

Venture Capital Spotlight

The Conference opened with a spotlight on venture capital, in a panel moderated by David Cassak in conversation with Joe Cunningham from Sante Ventures and David McIntyre from Apple Tree Partners in discussion with David Cassak.  Sante Ventures and Apple Tree Partners are two new funds that are actively investing in early stage medtech.

Sante Ventures go in typically at Series A round and are generally first institutional investor, said Cunningham.  David McIntyre said that he does not find two areas appealing, digital health and diagnostics, more so because he does not have deep background in investing in digital health; but things are moving in that direction and they have looked at some wearables.  Cunningham also said, “We have done more medtech than IT, and when we look at digital health, we look for profound changes”.

Emphasizing the importance of cost cutting in healthcare, Cunningham said, “if you go out on the street and ask people about the brand of hip or knee replacement they favor, they couldn’t tell you; in healthcare it is not so much about the brand, but the cost”.

PS – Please check out exciting jobs offering opportunities to work with disruptive technologies in JOBS category on this blog & please send leads or resume at wd_darshana at hot mail dot com.

Leave a comment

2016 Health Technology Forum (preview): tackling complex healthcare challenges with gentler focus on “Common Good”

Enabling people to have access to affordable healthcare is not only a challenge for the United States but a significant challenge in many parts of the world.  Given the current population trends, this challenge is going to become more complex and will need creative and out of the box solutions.  With aging populations, lack of clean air and water, and densely crowded mega cities, many people word-wide do not have quick and easy access to meet basic healthcare needs.  Further, rise in chronic diseases like obesity and diabetes, and amazing advances in diagnosing and treating diseases, people are living longer, and very likely will require medical care for longer periods.  

It is likely for instance, that in the next 30 years, the number of Alzheimer’s patients in the US can rise to 20 million.  While state of the art healthcare could be a available to a few in a Western nation like the US, there is a widening chasm between availability of healthcare to the top 1% of population and huge numbers at the bottom of the money pyramid.  According to US Census Bureau, approximately 49 million Americans lacked continuous access to basic healthcare on account of not having healthcare coverage, in 2011.  

Globally, the issues may be slightly different but the question for affordable access to healthcare is just as significant.  Nearly 2.6 billion people worldwide lack proper sanitation facilities, and almost a sixth of the world’s population don’t have access to adequate drinking water.

Health Technology Forum (HTF) attempts to tackle this complex challenge from one vantage point of connecting people worldwide, with common interest in making healthcare better, more accessible, and affordable for everyone, through the use of technology.  HTF is creating the environment for healthcare entrepreneurs, developers, regulators, and community health providers to come together for “common good”, to engage in productive dialogue for creative global solutions, for access to affordable healthcare.  By creating the space for this dialogue and for vital collaborations between healthcare innovators, providers and thought and business leaders, world takes one more tiny step forward to solving its most vexing healthcare challenge.

The 2016 HealthTech Innovation Conference will be on May 22 and 23 at Stanford University.   Pronoy Saha,
 CEO & founder of HealthTech Forum is working tirelessly to make his vision of wide access to affordable healthcare into a reality.  The conference agenda includes great panels and keynotes.  A panel on home and community innovations, will focus on technology advances that can enable people to live longer in their homes.  A panel of medical providers and other experts will discuss new business models for making precision medicine available to the masses, using genomics data, patient generated data, and social data.  A panel of leading investors in healthcare technology will discuss funding trends and will share insights on the criteria they use to determine what, when and who to fund.  This will be an exciting conference tackling hard issues and complex challenges, with soft and gentler focus on the theme of “Common Good”.  Please register at  and don’t forget to bring along business cards.  

Leave a comment

Enhanced Processing of Microscopy Data to Accelerate Research, Speed & Accuracy


Cassandra Boyer and Marc Bruce, Co-founders of Microvolution talked about software based technology to help accelerate medical research, at event.

The primary application of this technology is in microscopy. Traditionally, it takes several minutes to hours for microscopy images to be focused. The process of focusing digital images with mathematical algorithms is called deconvolution. Existing deconvolution technology requires researchers to wait several hours to days to know Shapeif their experiment is a success or a failure, this uses up a great deal of time and causes huge waste because the researcher does not have the proper knowledge to make adjustments to failed experiments in real time.  Because the current software on the market is slow and arduous to use, scientists often make important decisions from images that are blurry and hazy; thus, missing important details leading to low level of accuracy.


Boyer spoke of Microvolution’s deconvolution technology that enhances the speed and accuracy of medical research. Microvolution starts with the Richardson Lucy Algorithm which was originally invented by NASA to deconvolve (focus) the images from the Hubble Space Telescope. Other vendors use this algorithm, but must make mathematical shortcuts in order to achieve speed with their CPU-based software. These shortcuts result in missing data, such as thin filaments that are missing in the image. Microvolution makes no mathematical shortcuts because it harnesses the speed of the GPU, so images are deconvolved with more accuracy—all data are preserved.

Additionally, Microvolution adds unique mathematical algorithms that no other vendor offers which further enhance the accuracy of the images. Microvolution software delivers the most accurate and fastest deconvolution on the market by combining intelligent software programming with the power of a GPU, coupled with unique mathematical algorithms.

Microvolution software improves and enhances the quality of medical research in several significant ways.
* Enhances Speed: Microvolution is up to 200 times faster compared to more traditional approaches. Because Microvolution is so fast, researchers can try different settings with ease in order to optimize the settings so the best possible image is generated. Also, by capturing more images in less time—data sets improve.
* Empowers Researchers to Diminish Phototoxicity and Photobleaching: In traditional microspcopy, imaging with a high power light beam can cause significant damage to the sample. By incorporating Microvolution into your process, every image can be deconvolved in real-time, thus enabling you to dim the light intensity in real-time and realize improved outcomes. Microvolution increases signal and decreases noise in low light conditions where photon counts are limited.
* Reducing Phototoxicity and Photobleaching: Tradition microscopy methods lead to photochemical destruction of dye or flurophores (photobleaching) and cell death due to phototoxicity. Microvolution allows the researcher to turn down light intensity in real-time and diminish photobleaching. By dimming the light during long-term, time-lapse, live-cell experiments, one may diminish the effects of phototoxicity with Microvolution—cells live longer and this leads to higher success rates.
* Improved Accuracy: In addition to the fact that Microvolution does not take mathematical shortcuts, Microvolution incorporates unique mathematical algorithms for Point Spread Function Models and offers unique noise reduction models. No other vendor uses these algorithms; hence, Microvolution’s accuracy is superior. Additionally, it is important to turn off noise suppression when comparing the data from 2 different images. Microvolution is unique in the industry because it enables you to turn off regularization—this enables you to generate accurate data comparisons between 2 images.
* Deep Tissue and Organoid Imaging: Microvolution’s Blind Deconvolution Option enables researchers to achieve better results when one images thick tissues, organioids and 3-D tissue structures.
* Cost and ease of use: Microvolution is very easy to use as was demonstrated during the presentation. Additionally, GPUs cost less than CPUs and by using GPUs, this frees up the CPUs for other tasks like responding to user input.
* Can integrate real-time deconvolution into existing workflow: Seamless, integrated and instantaneous deconvolution with Microvolution technology enhances success rates and increases productivity, said Boyer.

Microvolution is unique in the industry because it offers the ability to use multiple GPU’s at once. This helps researchers deconvolve very large images in seconds instead of hours. As microscopy techniques evolve, image sizes are getting larger; thus, making it more important to implement software that can handle very large images sizes with ease. Microvolution offers instantaneous and integrated deconvolution for widefield, confocal, two-photon, light sheet, and HCA microscopes with the convenience of a MetaMorph® Drop-in or via an ImageJ/Fiji or Micro-Manager 2.0 Plugin.

Marc Bruce demonstrated the speed and accuracy of Microvolution’s software by deconvolving several raw images in seconds during the live demonstration. Clearly, Microvolution technology seems to offer superior processing of microscopy data. The event was followed by Q&A.

Leave a comment

Drug Development Panel Preview – EPPICon, 2016

Traditionally, the process of research and development, in the pharmaceutical industry, is very costly and time consuming, with small chance of a successful outcome.  When regulatory and reimbursement challenges and commercial realities and constraints of the business are added to the mix, it makes for a path fraught with unprecedented obstacles, with high stakes.

However, the current revolution in new technologies for biomarker testing and advances in public and private human genome projects, is revolutionizing drug development, reducing cost, and optimizing chances for success.  Exciting panel will discuss fast changing Drug Development process, at EPPICon, 2016.

Anil Singhal is Vice President of AbbVie and Head of AbbVie Biotherapeutics.  Prior to that he has held leadership positions at Abbott/ AbbVie and oversaw two phase 3 programs, daclizumab for multiple sclerosis and elotuzumab for multiple myeloma.  Singhal has held senior positions in various US, Japanese and German pharmaceutical and biotech companies and has led many cross-functional development teams.

Carlos Garcia, Director of Technical Operations at Gilead Sciences, leads biological program simtuzumab (GS-6624) for idiopathic pulmonary fibrosis.  As the Technical Operations and Regulatory Operations leader, he is also responsible for Gilead global biologics technical regulatory strategy and management.  

Trigemina, Inc. is a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products.  Dr. Shashi Kori has been appointed to the position of chief medical officer.  With his extensive experience in clinical trial design, he would likely see Trigemina’s intranasal oxytocin product for migraine headaches through late stage clinical trials.  

This is an exciting panel of industry experts.  Diagnostic breakthroughs typically precede therapeutic progress, and as more progress is being made in uncovering genetic roots of diseases, better understanding of disease progression, and treatment effectiveness, and as there has also been a growing enthusiasm for more sophisticated diagnostics and monitoring tests, now the question is how all this will alter and impact innovation in drug development.  Don’t miss the opportunity to hear from these industry stalwarts.  Register today at, before early bird price expires.

Leave a comment

%d bloggers like this: